Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

tinuation, this patient had undetectable HCV RNA. R7128 was generally safe and well-tolerated when administered for 4 weeks in combination with Pegasus plus Copegus in patients with HCV genotype 1.

Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

Conference Call

Pharmasset will host a conference call at 1:00 PM ET (US) and 7:00 PM CEST (Milan) on Friday, April 25, 2008 to discuss the R7128 500mg and 1500mg combination study results, as well as the addition of two R7128 cohorts to the on-going Phase 1 protocol.

Dial-in Information:

US/Canada Toll-Free callers: +1 (877) 545-1490

US/Canada Toll or International Toll callers: +1 (719) 325-4884

Live audio of the conference call will be simultaneously broadcast over the internet via a webcast. To access the live webcast, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's corporate website at http://investor.pharmasset.com/events.cfm .

Please connect to the company's website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary to listen to the webcast. The archived replay of the webcast will be available on the Pharmasset website for two weeks following the conference call.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... 2014  ResMed (NYSE: RMD ), a pioneer ... to design complete sleep apnea solutions specifically for women, is ... of a good night,s sleep. The Better ... feeling tired is just part of living a busy life. ... critical pillar of health, essential to not only living an ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems (NYSE: ... report results for the fourth quarter of fiscal year ... October 22, 2014.  The news release will be followed ... 2:00 p.m. PT.  The news release and a link ... the company website at: www.varian.com/investor .  To access ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) ... -- may face an increased risk of dying in the next ... 3,000 older Americans, researchers found those who were unable to detect ... times as likely to die in the next five years, versus ... -- the inability to distinguish odors -- was a bigger predictor ...
(Date:10/2/2014)... scientists at The University of Nottingham could lead to ... , A drug resulting from the research, published in ... new hope to sufferers of chronic pain conditions such ... are currently available. , The work, led by Dr ... in collaboration with David Bates, Professor of Oncology in ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... the Engineering and Physical Sciences Research Council (EPSRC) ... vital industrial control systems which run, for example, ... the rail network. , The research will ... malware infiltrating the systems behind our critical national ... Industrial Control Systems (RITICS), based at Imperial College ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... who cares for patients with cancer at The Children,s Hospital ... Junior Faculty Award in Pediatric Oncology. The American Society of ... award during its annual meeting, occurring June 1-5 in Chicago. ... B. Nachman, a pediatric oncologist and Professor of Pediatrics at ...
... TUESDAY, May 8 (HealthDay News) -- Eating too quickly may ... Researchers from Lithuania compared 234 people with type 2 ... those who gobble down their food were 2.5 times more ... while eating. Study participants with diabetes also were more ...
... Branch at Galveston researchers have discovered that a drug ... also have another important use: treating one of the ... rat and cell-culture experiments, the scientists found that metformin, ... in type 2 diabetes, also substantially reduced the effects ...
... physicians, fees under Medicare which in turn influence ... will pay doctors -- the Centers for Medicare and ... American Medical Association advisory panel. A study led by ... Public Health, found that the Medicare and Medicaid agency ...
... Reporter , MONDAY, May 7 (HealthDay News) -- Those suffering ... their symptoms, but a cure has yet to be found. ... may help patients suffer a little less, but side effects ... preparations impact symptoms of the common cold, there is currently ...
... -- The Medical Publishing Insights and Practices (MPIP) ... editors to characterize the persistent and perceived credibility ... potential approaches to resolve it. This unique round ... Recommendations for Closing the Credibility Gap in Reporting ...
Cached Medicine News:Health News:Diabetes drug could treat leading cause of blindness 2Health News:AMA committee recommendations on doctor fees set by Medicare are followed 9 times out of 10 2Health News:Zinc Pills May Shorten Colds, Analysis Suggests 2Health News:Journals and pharma collaborate on new recommendations 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: